Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials | Zendy

Angela T.H. Kwan | Zendy; Saman Arfaie | Zendy; Joseph Therriault | Zendy; Pedro RosaNeto | Zendy; Serge Gauthier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials

Author(s) -

Angela T.H. Kwan,

Saman Arfaie,

Joseph Therriault,

Pedro RosaNeto,

Serge Gauthier

Publication year - 2020

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000511506

Subject(s) - clinical trial , medicine , monoclonal antibody , amyloid (mycology) , asymptomatic , antibody , immunology , pathology

Alzheimer disease (AD) is a chronic neurodegenerative disorder with complex pathophysiology that affects over 50 million people worldwide. Most drug therapies, to date, have focused on targeting the amyloid-beta (Aβ) pathway, but clinical outcomes of anti-Aβ antibodies have been unsuccessful and unable to meet their primary endpoints. Similar trends have also been observed in treatments that target the tau pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research